BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.

Tanguy Y. Seiwert, Ezra E.W. Cohen, Didier Cupissol et al.|Journal of Clinical Oncology|2010

Cited by 39